约旦大学医院高血压患者缬沙坦反应相关因素的预测

Q2 Pharmacology, Toxicology and Pharmaceutics Drug metabolism and personalized therapy Pub Date : 2025-02-06 eCollection Date: 2025-03-01 DOI:10.1515/dmpt-2024-0088
Shahd Khalil, Aseel Quran, Leen Thalji, Malk Al-Adamat, Lina Sabha, Joud Khraisat, Abdel Rahman Al Na'ami, Hatem Al-Jazzazi, Hussein Alhawari, Yazun Jarrar
{"title":"约旦大学医院高血压患者缬沙坦反应相关因素的预测","authors":"Shahd Khalil, Aseel Quran, Leen Thalji, Malk Al-Adamat, Lina Sabha, Joud Khraisat, Abdel Rahman Al Na'ami, Hatem Al-Jazzazi, Hussein Alhawari, Yazun Jarrar","doi":"10.1515/dmpt-2024-0088","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>There is an inter-individual in the valsartan response among hypertensive patients. However, clinical factors associated with this variation in the response is still not fully understood. The major purpose of this study is to predict the factors associated with valsartan response and their influence on decreasing blood pressure among patients.</p><p><strong>Methods: </strong>This study is a cross-sectional observational study. It included 91 hypertensive patients on valsartan treatment, selected through simple random sampling from the Jordan University Hospital. The clinical data was collected through documented medical records in the hospital's computerized system. The data was analyzed using the chi-square test to compare frequencies and categories.</p><p><strong>Results: </strong>Patients were divided into systolic and diastolic responders. No statistical significance was found between systolic response to valsartan's and gender, smoking, age, BMI, lipid profile and HbA<sub>1c</sub> status. Diastolic responders had a positive significance of p-value = 0.006 with BMI categories, however there was no significance with any other factor.</p><p><strong>Conclusions: </strong>There was a better diastolic response to valsartan among hypertensive patients with lower BMI levels. BMI can be considered as a factor to personalize the therapy among patients on valsartan. However, further clinical studies with larger sample size are needed to confirm these data.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"69-75"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predicting of factors associated with valsartan response among hypertensive patients attending the Jordan University Hospital.\",\"authors\":\"Shahd Khalil, Aseel Quran, Leen Thalji, Malk Al-Adamat, Lina Sabha, Joud Khraisat, Abdel Rahman Al Na'ami, Hatem Al-Jazzazi, Hussein Alhawari, Yazun Jarrar\",\"doi\":\"10.1515/dmpt-2024-0088\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>There is an inter-individual in the valsartan response among hypertensive patients. However, clinical factors associated with this variation in the response is still not fully understood. The major purpose of this study is to predict the factors associated with valsartan response and their influence on decreasing blood pressure among patients.</p><p><strong>Methods: </strong>This study is a cross-sectional observational study. It included 91 hypertensive patients on valsartan treatment, selected through simple random sampling from the Jordan University Hospital. The clinical data was collected through documented medical records in the hospital's computerized system. The data was analyzed using the chi-square test to compare frequencies and categories.</p><p><strong>Results: </strong>Patients were divided into systolic and diastolic responders. No statistical significance was found between systolic response to valsartan's and gender, smoking, age, BMI, lipid profile and HbA<sub>1c</sub> status. Diastolic responders had a positive significance of p-value = 0.006 with BMI categories, however there was no significance with any other factor.</p><p><strong>Conclusions: </strong>There was a better diastolic response to valsartan among hypertensive patients with lower BMI levels. BMI can be considered as a factor to personalize the therapy among patients on valsartan. However, further clinical studies with larger sample size are needed to confirm these data.</p>\",\"PeriodicalId\":11332,\"journal\":{\"name\":\"Drug metabolism and personalized therapy\",\"volume\":\" \",\"pages\":\"69-75\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug metabolism and personalized therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/dmpt-2024-0088\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism and personalized therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/dmpt-2024-0088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

目的:高血压患者对缬沙坦的反应存在个体间差异。然而,与这种反应变化相关的临床因素仍未完全了解。本研究的主要目的是预测缬沙坦反应的相关因素及其对降低患者血压的影响。方法:本研究为横断面观察性研究。该研究包括91名接受缬沙坦治疗的高血压患者,通过简单随机抽样从约旦大学医院选择。临床数据是通过医院计算机系统中的医疗记录收集的。使用卡方检验对数据进行分析,比较频率和类别。结果:患者分为收缩期和舒张期两组。缬沙坦的收缩期反应与性别、吸烟、年龄、BMI、血脂和HbA1c状态之间无统计学意义。舒张反应者与BMI分类有显著性差异(p值= 0.006),与其他因素无显著性差异。结论:BMI较低的高血压患者对缬沙坦有更好的舒张反应。BMI可作为缬沙坦患者个体化治疗的一个因素。然而,这些数据需要进一步的更大样本量的临床研究来证实。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Predicting of factors associated with valsartan response among hypertensive patients attending the Jordan University Hospital.

Objectives: There is an inter-individual in the valsartan response among hypertensive patients. However, clinical factors associated with this variation in the response is still not fully understood. The major purpose of this study is to predict the factors associated with valsartan response and their influence on decreasing blood pressure among patients.

Methods: This study is a cross-sectional observational study. It included 91 hypertensive patients on valsartan treatment, selected through simple random sampling from the Jordan University Hospital. The clinical data was collected through documented medical records in the hospital's computerized system. The data was analyzed using the chi-square test to compare frequencies and categories.

Results: Patients were divided into systolic and diastolic responders. No statistical significance was found between systolic response to valsartan's and gender, smoking, age, BMI, lipid profile and HbA1c status. Diastolic responders had a positive significance of p-value = 0.006 with BMI categories, however there was no significance with any other factor.

Conclusions: There was a better diastolic response to valsartan among hypertensive patients with lower BMI levels. BMI can be considered as a factor to personalize the therapy among patients on valsartan. However, further clinical studies with larger sample size are needed to confirm these data.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Drug metabolism and personalized therapy
Drug metabolism and personalized therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
2.30
自引率
0.00%
发文量
35
期刊介绍: Drug Metabolism and Personalized Therapy (DMPT) is a peer-reviewed journal, and is abstracted/indexed in relevant major Abstracting Services. It provides up-to-date research articles, reviews and opinion papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion. Topics: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug-drug interactions, immunopharmacology, neuropsychopharmacology.
期刊最新文献
Allergic reactions to anaesthetics in surgery: current challenges and perspectives. Superior seizure control with first-line levetiracetam in very low birth weight neonates: a 10-year comparative retrospective study. Allele frequencies of pharmacogenetic biomarkers and genomic ancestry in a sample of the Cuban population. The 10+2 Santorini conference: systems medicine and personalised health therapy. The odyssey from hope to practice: "patient first - keep Ithaca always in your mind" Santorini, Greece, 26-29 May 2026. Drug metabolism and personalized therapy is switching its publication model to open access.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1